Milestone Pharmaceuticals Inc. (MIST) Financial Analysis & Valuation | Quarter Chart
Milestone Pharmaceuticals Inc. (MIST)
MISTPrice: $1.36
Fair Value: 🔒
🔒score
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia i... more
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commerci... more
Description
Shares
| Market Cap | $115.83M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CA | CEO | Joseph G. Oliveto |
| IPO Date | 2019-05-09 | CAGR | — |
| Employees | 33 | Website | www.milestonepharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MIST chart loading...
Fundamentals
Technicals
| Enterprise Value | $154.77M | P/E Ratio | -2.13 |
| Forward P/E | -2.57 | PEG Ratio | — |
| P/S Ratio | 80.66 | P/B Ratio | 2.73 |
| P/CF Ratio | -2.32 | P/FCF Ratio | -2.36 |
| EPS | $-0.79 | EPS Growth 1Y | 13.04% |
| EPS Growth 3Y | 25.81% | EPS Growth 5Y | -58.73% |
| Revenue Growth 1Y | inf% | Gross Margin | -0.06% |
| Operating Margin | -43.39% | Profit Margin | -55.28% |
| ROE | -8.27% | ROA | -0.7% |
| ROCE | -0.63% | Current Ratio | 8.01 |
| Quick Ratio | 7.96 | Cash Ratio | 5.23 |
| Debt/Equity | 1.4 | Interest Coverage | -8.3 |
| Altman Z Score | -4.97 | Piotroski Score | 2 |